As­traZeneca's Imfinzi com­bo ex­tends PFS in liv­er can­cer; No­var­tis shares new de­tails about Lu­tather­a's PhI­II

Here are the lat­est da­ta from AS­CO’s Gas­troin­testi­nal Can­cers Sym­po­sium:

Imfinzi com­bo ex­tends pro­gres­sion-free sur­vival in liv­er can­cer: In a Phase III tri­al, As­traZeneca’s Imfinzi plus be­va­cizum­ab, oth­er­wise known as Avastin, on top of a stan­dard care chemother­a­py treat­ment called TACE for liv­er can­cer, staved off can­cer pro­gres­sion longer than the chemother­a­py treat­ment alone. The EMER­ALD-1 study in­clud­ed over 600 pa­tients with he­pa­to­cel­lu­lar car­ci­no­ma, which is the most com­mon form of liv­er can­cer and can’t be re­moved by surgery. How­ev­er, these pa­tients were el­i­gi­ble for em­boliza­tion, the pro­ce­dure used for TACE.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER